Moderna’s personalized mRNA shot could reshape the fight against skin cancer — but it may also be overhyped

Moderna is developing a personalized mRNA vaccine designed to treat melanoma in combination with Merck's Keytruda immunotherapy. The vaccine showed a 44 percent reduction in recurrence or death risk in a clinical trial, according to data released by the company. Some analysts have expressed caution about market expectations, while dermatologists and oncologists have cited the trial results as a potential advance in melanoma treatment.

Next story